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1. Introduction
Bacterial inclusion bodies (IBs) are insol-
uble and discrete particles highly enriched 
by a single protein species, which deposits 
as interdigitated amyloidal fibers and nona-
myloidal protein forms.[1] They organize 
into porous fibrilar networks[2] that confer 
mechanical stability, in which native or 
quasinative protein species are embedded.[3] 
These protein clusters, ranging between 
the nano- and micro-scales, are built up in 
Two structurally and functionally unrelated proteins, namely Omomyc 
and p31, are engineered as CD44-targeted inclusion bodies produced in 
recombinant bacteria. In this unusual particulate form, both types of protein 
materials selectively penetrate and kill CD44+ tumor cells in culture, and upon 
local administration, promote destruction of tumoral tissue in orthotropic 
mouse models of human breast cancer. These findings support the concept 
of bacterial inclusion bodies as versatile protein materials suitable for 
application in chronic diseases that, like cancer, can benefit from a local slow 
release of therapeutic proteins.
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bacterial cells upon expression of a recombinant gene encoding 
the IB protein. Upon purification from bacteria, they behave as 
mechanically stable biomaterials,[4] easy to be handled in a diver-
sity of platforms, presentations and interfaces. In this regard, IBs 
have been explored in the context of tissue engineering as soft 
topographies[4] since they are nontoxic to mammalian cells.[5]
Being partially composed of functional polypeptides,[6] IB 
enzymes have found a role in industrial applications as self-
immobilized catalysts.[7] In addition, IBs tend to attach and 
penetrate mammalian cells without any deleterious effect,[8] via 
macropynocytosis.[9] Since part of the functional IB protein is 
released under physiological conditions (namely cell culture 
media, intracellular environment upon uptake, or in organic 
tissues),[9] IBs act as slow release protein platforms, potentially 
useful in therapeutic approaches (at both cell or organism levels) 
for protein replacement therapies or protein drug delivery.[8,10,11] 
If the IB protein is targeted to a biological marker, for instance, 
through the incorporation of a tumor-homing peptide, IBs 
can remotely deliver IB proteins through the bloodstream to 
tumoral tissues upon subcutaneous administration.[12] The 
bulk IB material, however, is partially stable in the adminis-
tration site and it remains detectable for weeks long.[13] Then, 
once implanted, IBs act as local protein depots, mimicking the 
natural amyloid repositories of human hormones in the endo-
crine system,[14] found them listed among examples of the 
expanding catalogues of nontoxic functional amyloids.[15] In this 
context, extracellular activities of IB proteins, either attached to 
IBs or upon release, are responsible for downregulation of cell 
surface receptor expression (by the display of a peptidic ligand 
of a cytokine receptor[13]) or for enhanced cell growth (when 
formed by a growth hormone[8]), through appropriate signaling. 
Whether and how IB proteins released in vivo can penetrate 
neighboring cells and interact with intracellular circuits for 
biological manipulation and therapeutic impact remains poorly 
explored despite its obvious pharmacological interest.
2. Results and Discussion
To investigate this issue, we have here designed two mod-
ular proteins formed by two functional polypeptides (p31 
and Omomyc, respectively) involved in cell cycle regulation, 
with therapeutic potential in antitumoral therapies as tumor-
targeting agents. The p31 protein consists of the C-terminal 
fragment of p130cas that has shown the ability to promote 
apoptosis by disassembling focal adhesion complexes.[16,17] 
The Omomyc protein is a Myc dominant negative[18] exten-
sively validated transgenically and pharmacologically as an 
antitumoral agent.[19–21] Both proteins were tagged with the 
tumor-homing peptide FNI/II/V (FN) which binds CD44, a 
glycoreceptor that promotes extracellular cell adhesion through 
hyaluronic acid interaction. CD44 is a well-recognized tumoral 
marker, associated to tumor progression and metastasis,[22,23] 
and that has been used to identify, along with low expression 
of CD24, the cancer stem cell population in breast cancer.[24] 
Therefore, the use of the tumor-homing peptide FN seemed 
appropriate to test targeted nanodepots in a tumor type, the 
triple negative breast cancer, that currently lacks targeted thera-
pies.[25] The modular proteins FN-p31-H6 and Omo-FN-H6 
(Figure 1A) were produced in Escherichia coli as proteolytically 
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Figure 1. Proteins and protein materials. A) Schematic representation of the fusion proteins FN-p31-H6 and Omo-FN-H6, indicating the molecular 
mass of the products. Control proteins used in the study (FN-GFP-H6 and GFP-H6,[26]) are also included. Box sizes are only approximate. B) Coomassie 
blue staining of a SDS-PAGE gel loaded with purified proteins. Numbers on the left indicate the molecular masses in kDa of the ladder marker. On the 
right, arrows indicate the position of the full-length recombinant proteins. M indicates the molecular marker line, and p31 and O indicate FN-p31-H6 
and Omo-FN-H6 lanes, respectively. C) Internalization of FN-GFP-H6 in cultured CD44+ MDA-MB-231 and CD44− HepG2 cells, measured as the % of 
green fluorescent cells. Protein was added at 0.5 × 10−6 m and exposed to cells for 24 h. The percentage of CD44+ cells in each cell line is also indicated 
as a reference. D) Representative FESEM images of FN-p31-H6 and Omo-FN-H6 IBs at two different magnifications (zoom in the insets). Magnifica-
tions are equivalent in each micrograph pair to allow comparative visualization. Magnification bars represent 500 nm.
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stable full-length polypeptides (Figure 1B). FN-GFP-H6[26] was 
also produced as a fluorescent reporter, and this protein was 
found able to penetrate into 55.6% of CD44+ MDA-MB-231 
cells after 24 h of exposure, but not into CD44− HepG2 cells 
(7.4%, Figure 1C). This data fully supported the CD44 tar-
geting of the FN segment and the further exploration of FN-
empowered IBs as CD44-targeted agents. Upon production, 
an important population of FN-p31-H6 and Omo-FN-H6 was 
found in the insoluble cell fraction, aggregated in the form of 
IBs (Figure 1D). After purification from bacterial cell extracts, 
p31 and Omomyc IBs were clearly distinguishable in shape 
and morphology. While the first ones organized in a rod-shape 
architecture (≈200 × 1000 nm) with a smooth surface, as previ-
ously described for some nonconventional IBs,[27] Omomyc IBs 
were smaller (≈200 × 500 nm), exhibiting a rough surface and 
an ellipsoid geometry that is much more common among bac-
terial IBs.[28]
To first explore the potential of these IBs to impact tumor 
cell biology, cultured breast cancer human MDA-MB-231 
cells overexpressing CD44[24,29] were exposed to either p31 or 
Omomyc IBs and appropriate GFP controls. Both p31 and 
Omomyc IBs showed a dose-dependent cytotoxic effect on cell 
viability, not observed when exposing cells to GFP-based IBs 
(Figure 2A). The lack of toxicity associated to exposure to GFP 
IBs fully confirmed the protein-associated toxicity of IBs, as the 
IB material, per se, is not intrinsically cytotoxic.[1] Moreover, 
while p31 IBs showed an increasing cell killing potential with 
longer exposure time, Omomyc IBs showed the highest effi-
cacy already at 48 h post exposure, indicating a faster mecha-
nism of action (Figure 2B). Similar cytotoxic effects of p31 and 
Omomyc IBs on cell viability were observed in multiple CD44+ 
cell lines,[23] reaching slightly different extents probably due to 
intrinsic differences in cell survival mechanisms, while GFP-
based IBs remained nontoxic (Figure 2C). Microscopy images 
of MDA-MB-231 cultured cells exposed to active and nonac-
tive materials, fully confirmed the cytotoxicity promoted by 
functionalized IBs (Figure 2D). Indeed, functional IBs caused 
a clear reduction in tumor sphere size when compared to the 
GFP ones.
Since both p31 and Omomyc perform their activities intra-
cellularly, cell uptake of IBs can be inferred from the cytotox-
icity exhibited by these materials on cultured cells, in contrast 
with the absence of effect shown by control GFP IBs (Figure 2). 
However, to effectively assess the cell penetrability of cytotoxic 
IBs, these materials were labeled with AF647. When MDA-MB-
231 cells were exposed to labeled IBs, intracellular fluorescence 
increased in a dose-dependent fashion when cells were exposed 
to FNI/II/V functionalized IBs (Figure 3A). However, GFP-H6 
IBs, which lack a cell ligand, did not accumulate in CD44 target 
cells (Figure 3A). This confirms that cell targeting of IBs for 
specific protein delivery is a feasible concept, not restricted to 
the CXCR4-binding T22 peptide, in which this event has been 
recently described for the first time.[30] Internalization efficacy 
of p31- and Omomyc- based IBs was comparable (Figure 3A,B) 
Adv. Sci. 2019, 1900849
Figure 2. Biological impact of IBs on cultured cells. A) Dose-dependent loss of MDA-MB-231 cell viability upon exposure to IBs for 96 h. At 9 × 10−6 m, 
background reduction of cell viability was observed in cells exposed to GFP-based IBs (not shown). B) Time-dependent loss of MDA-MB-231 cell 
viability upon exposure to IBs (3 × 10−6 m). C) Killing of different CD44+ cell lines by cytotoxic IB (3 × 10−6 m), upon exposure for 96 h. D) Representa-
tive bright field images of MDA-MB-231 tumor-spheres upon addition of 3 × 10−6 m protein and further incubation for 72 h. Qualitative assessment of 
sphere morphology and integrity when challenged with p31 and Omomyc IBs, compared to an equivalent GFP construct. Magnification bars represent 
100 µm. One-way ANOVA and a post-hoc Dunnett test was performed comparing all groups to PBS-treated control cells. p > 0.05 (n.s.); p < 0.05 (*); 
p < 0.01 (**); p < 0.001 (***).
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and with similar intracellular distribution (Figure 3C). Further-
more, FNI/II/V-functionalized IBs accumulated inside target 
cells overtime, a fact that is compatible with moderate or absent 
lysosomal degradation (Figure 3B). In this regard, the confocal 
analyses of the internalizing material revealed a punctuated flu-
orescence pattern indicative of an endosomal route of internali-
zation, and a perinuclear localization of most of the engulfed 
protein particles that was more evident in the case of p31 IBs 
(Figure 3C).
Because of the high penetrability capacity of CD44-targeted 
IBs in cultured cells, we decided to evaluate their potential 
macroscopic effect in vivo, in mouse cancer models. For a first 
screening of antitumoral effect, we chose to test Omomyc IBs, 
which had shown superior cytotoxicity in vitro compared to FN-
p31-H6. Omomyc IBs were injected intratumorally in an ortho-
topic animal model of human breast cancer and the biological 
impact of the administered materials on the tumor progres-
sion was evaluated in repeated dose administration (weekly) 
for 4 weeks. Although the general tumor volume measured 
by caliper was not significantly affected during the test period 
(Figure 4A), the proportion of necrotic tumors (Figure 4B) was 
clearly higher in the group of animals receiving Omomyc IBs 
compared to those in control groups (Figure 4C). This obser-
vation indicated destruction of tumoral tissue, which, although 
not reflected by any significant change in tumor volume, 
was representative of a relevant biological effect. Hence, the 
detected antitumoral effect was indicative of the functional IBs 
having an impact on the biology of tumoral target cells.
In parallel, we continued the characterization of p31-based 
IBs assessing their behavior in in vivo conditions. When these 
IBs were administered in a single dose, the fluorescent material 
was detected up to 7 d in the injection site, without apparent 
loss of emission (Figure 5A), confirming the stability of the pro-
tein particles. In this context, p21 overexpression (a cell cycle 
regulator usually associated to growth arrest and/or senes-
cence) was also clearly observed by immunodetection in tumors 
treated with FN-p31-H6 IBs (Figure 5B). Since the nuclear 
overexpression of p21 has been associated to the triggering of 
apoptotic cascades through the blocking of cyclin dependent 
kinases,[31] the presence of apoptotic cells was assessed in BT-20 
tumors upon single dose administration of FN-p31-H6 IBs, 
since these cells were the ones with the highest cell growth 
inhibition in vitro (Figure 2C). As observed in Figure 5C, a sig-
nificant increase in apoptotic cell bodies was clearly visible in 
FN-p31-H6 IBs treated tumors when compared with control 
animals, and overexpression of p21 was confirmed by Western 
Blot in BT20 cells exposed to both IBs (Figure 5D).
In summary, self-assembling proteins and protein mate-
rials are of emerging interest because of their intrinsic lack of 
toxicity, biodegradability, functional and structural versatility, 
and because of their suitability for biological fabrication in a 
diversity of microbial cell factories.[32] Some of them, such as 
the bovine α-lactalbumin[33] or the hen egg white lysozyme,[34] 
have already proved their utility as the basis of wide spectrum 
antitumoral drugs. Among the diversity of applications of 
protein constructs, bacterial IBs have found different prom-
ising niches in biomedical research,[35] as delivery systems 
of therapeutic proteins[8,11] or as convenient agents in immu-
noprophylaxis and immunotherapies.[36] The utility of this 
platform is based on the high mechanical stability of IBs 
combined with the ability of the particles to release functional 
proteins under physiological conditions both in vitro and in 
Adv. Sci. 2019, 1900849
Figure 3. Cell penetration of CD44-targeted IBs. A) Quantification of protein internalization by fluorescence was quantified with flow cytometry into 
MDA-MB-231 cells incubated for 24 h at increasing concentration of IBs. B) Kinetics of IB penetration into MDA-MB-231 cells exposed to 3 × 10−6 m 
IBs. C) Representative confocal microscopy images of protein internalization in MDA-MB-231 after 24 h treatment with 3 × 10−6 m of IBs. Nuclei and 
membrane cells were labeled with Hoechst (blue) and WGA (light grey) respectively. Magnification bars represent 5 µm.
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vivo in cell culture media,[37] the intracellular environment[9] 
or as locally administered in organs or tissues of entire organ-
isms.[13] Both the mechanical stability and capability of pro-
tein release are generic IB properties[38] supported by the 
particular sponge-like architecture (combining amyloidal and 
nonamyloidal protein forms) of IBs.[3] Protein released from 
subcutaneous IBs can reach the bloodstream and be remotely 
delivered to target organs, provided the IB protein incorpo-
rates appropriate ligands for cell surface receptors.[12] In addi-
tion, IBs are also nontoxic in vitro when exposed to cultured 
mammalian cells[4] or upon systemic administration (i.e., 
by oral delivery).[8] Therefore, these materials are promising 
as implantable protein depots for the release of functional 
polypeptides with therapeutic value aimed 
to the local or generic treatment of chronic 
diseases. A critical step in this direction 
would be to generate a proof of concept of 
the healing potential of the biomaterials in 
clinical contexts.
In this regard, we have here proved for the 
first time that two recombinant proteins with 
recognized antitumoral effects, empowered 
with a potent ligand of the tumoral marker 
CD44 (Figure 1), are able to significantly 
impact tumor cell biology (Figures 2,4, 
and 5) through the internalization of these 
biomaterials in target cells, both in vitro in 
cell culture (Figure 3) and in vivo in entire 
organisms (Figure 5). Indeed, we have dem-
onstrated here that upon efficient inter-
nalization, engineered versions of p31 and 
Omomyc, formulated as CD44-targeted IBs, 
promote selective target cell death through 
their respective impacts in regulatory cell 
circuits.
Omomyc anti-tumor activity is based 
on its direct interference with Myc func-
tion. Myc has been shown to be involved in 
multiple aspects of tumorigenesis,[39] both 
at the intracellular and extracellular level, 
being responsible for cell division, increased 
cell metabolism, immune tolerance, and 
survival to treatment of tumor cells. The 
benefit of inhibiting Myc has been demon-
strated by multiple studies,[19] which indi-
cated that interfering with Myc function 
does not only lead to cell growth arrest, but 
also to energetic crisis, anti-tumor immune 
reprogramming, and cancer cell death. 
Omomyc has been instrumental in demon-
strating this therapeutic opportunity, first as 
a transgene[20] and more recently as a thera-
peutic polypeptide,[40] while also demon-
strating the complete safety of the approach 
for normal tissues. The potential use of 
Omomyc as a therapeutic mini-protein has 
only emerged recently[40,41] and, to date, this 
is the first and only report of its application 
in the IB format, which establishes the fea-
sibility of its topical administration by intratumoral injection 
directly to the tumor site.
P31, so far neglected regarding its potential uses as a thera-
peutic agent, has been directly linked to the control of p21 expres-
sion and pro-apoptotic activity, especially in triple negative breast 
cancers (TNBC).[42] The present study proves that P31 is packable 
as IBs while keeping relevant antitumoral functionalities. This is 
not only pertinent regarding the incorporation of this protein to 
the growing catalogue of putative protein drugs, but also because 
it indicates that the engineering of antitumoral IBs is a general 
concept not restricted to a specific polypeptide. Importantly, the 
IB format itself is nontoxic, as CD44-targeted GFP IBs do not 
cause any deleterious effects over exposed cells (Figure 2).
Adv. Sci. 2019, 1900849
Figure 4. Antitumoral effect of IBs. A) Effect of Omomyc-based IBs on tumor growth. Balb/c 
nude female mice bearing orthotopic tumors of MDA-MB-231 cell line were divided in 5 groups 
(n = 7–8) and treated intratumorally (i.t.) once a week. One group was treated with Omomyc 
IBs. GFP-based IBs and PBS were included as treatment controls. No significant effect on 
tumor volume between the treatment groups was detected. B) Tumor necrosis was also evalu-
ated at the experiment end point. Representative images are shown. C) The percentage of 
necrotic tumors for the groups treated with either IBs was measured. Omomyc IBs treated mice 
showed an increase in the number of necrotic tumors compared to GFP IB-treated animals.
www.advancedsciencenews.com
1900849 (6 of 9) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
3. Conclusions
Since the biological production of IBS is cost-effective, using 
this material appears to be a convenient way of local adminis-
tration of protein drugs. Considering the increasing spectrum 
of therapeutic proteins already approved or under development 
for cancer therapies, most of them produced by recombinant 
DNA technologies,[43] their potential packaging as IBs might 
largely expand their spectrum of activities and applicability in 
innovative and personalized medicines, for oncology and in 
other fields of human or animal clinics.
4. Experimental Section
Protein Design, and IB Production and Purification: Two modular 
proteins were designed to contain the CD44 ligand FNI/II/V fused to 
either p31 (the C-term fragment of p130cas) or Omomyc (the Myc-
derived bHLHZip domain mutant), appended with a His-tag (Figure 1). 
The FNI/II/V domain was placed at the N- or C-terminus of p31[17] 
and Omomyc-containing modular protein respectively, considering 
preliminary results which showed no impact on protein activity. The amino 
acid sequences of the fusion proteins are MWQPPRARITGYIIKYEKP-
GSPPREVVPRPRPGVTEATITGLEPGTEYTIYVIALKNNQKSEPLIGRKK
TGGSSRSSSGQYENSEGGWMEDYDYVHLQGKEEFEKTQKELLEKGSI
TRQGKSQL ELQQLKQFERLEQEVSRPIDHDLANWTPAQPLAPGRTG-
GLGPSDRQLLLFYLEQCEANLTTLT NAVDAFFTAVATNQPPKIFVAHSKFV
ILSAHKLVFIGDTLSRQAKAADVRSQVT HYSNLLCDLLRGIVATTKAAALQ
YPSPSAAQDMVERVKELGHSTQQFRRVLGQLAAAGGSSRSSSKHHHHHH 
(FN-p31-H6) and MTEENVKRRTHNVL ERQRRNELKRSFFALRDQIPELENNEK
APKVVILKKATAYILSVQAETQKLISEIDLL RKQNEQLKHKLEQLRNSCAGGSSRSS
SWQPPRARITGYIIKYEKPGSPPREVVPRPRPG VTEATITGLEPGTEYTIYVIALK-
NNQKSEPLIGRKKTGGSSRSS SKHHHHHH (Omo-FN-H6) respectively. 
FN-p31-H6 and Omo-FN-H6 genes, together with the biologically 
inactive control gene FN-GFP-H6 and nontargeted GFP-H6 control gene, 
were provided by GenScript (Hong Kong, China). Recombinant proteins 
were produced in E. coli strain BL21 (DE3), except Omo-FN-H6 that was 
produced in BL21 pLys cells. Protein production was usually induced at 
37 °C for 3 h upon 1 × 10−3 m IPTG addition. FN-GFP-H6 protein was 
produced overnight at 16 °C. Bacterial IBs were purified upon protein 
Adv. Sci. 2019, 1900849
Figure 5. In vivo biodistribution and efficacy of FN-p31-H6 IBs. A) Mice bearing orthotopic tumors of HCC1806 cell line were treated intratumorally 
(i.t.) with p31 IBs labeled with the AF647 fluorochrome. In vivo imaging was performed with IVIS-Spectrum 0, 4, and 7 days after administration (left 
panel) and quantified (right top panel). No fluorescence was observed outside the tumors (not shown). Ex vivo imaging (right bottom panel) confirmed 
that fluorescence was retained in the tumors, with higher intensities at the site of injection. B) Representative images of p21 protein expression by 
immunohistochemistry in tumors of animals treated i.t. with control GFP or p31 IBs, showing that only p31 containing IBs were able to induce p21 
expression, in BT-20 orthotropic tumors. Quantitative evaluation of the stained section confirmed that p21 staining was significantly higher in tumors 
of p31 IBs-treated mice (right panel). C) Representative images of Hoechst staining of control FN-GFP-H6-treated and p31 IBs-treated mice. Arrows 
indicate the presence of characteristic apoptotic nuclei. Quantification of apoptotic nuclei in control and FN-p31-H6 treated tumors indicated that 
apoptosis was significantly increased upon treatment with p31 IBs (right panel). Magnification bars in (B,C) represent 100 and 50 µm, respectively. 
p < 0.01 (**); p < 0.001 (***). D) p21 expression in BT20 cells treated for 4 h with FN containing constructs.
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production; cells were incubated 2 h at 37 °C with a Protease Inhibitor 
Complete tablet, 10 × 10−3 m PMSF and 1 µg mL−1 lysozyme. Then, 
cultures were treated with 0.1% Triton X-100 for 1 h at room temperature 
(RT). Cycles of freeze/thaw were applied daily to destroy remaining 
bacteria until reaching CFU mL−1 < 10−2. Samples were incubated with 
0.02% NP-40 for 1 h at 4 °C followed by 1 h incubation with 1 µg mL−1 
DNAse at 37 °C. IBs obtained after centrifugation at 15 000 g were 
washed twice with PBS, separated in 1 mL aliquots and stored at −80 °C 
in PBS. A milder purification protocol was applied for GFP-H6 IBs 
isolation. After the incubation with PMSF and lysozyme, cells were 
lysed using a French Press at 1200 psi. Lysates were treated with 0.1% 
Triton X-100 for 1 h at RT followed by 1 h incubation with 1 µg mL−1 
DNAses at 37 °C. Cycles of freeze/thaw were applied daily until reaching 
CFU mL−1 < 10−2. IBs were centrifuged, washed twice in PBS and stored 
at −80°C in PBS in 1 mL samples.
IB Protein Quantification: Serial dilutions of 1 mL IB samples were 
prepared in water with Laemmli buffer and incubated at 98 °C for 45 min. IB 
dilutions together with a soluble GFP-H6 standard of known concentration 
were loaded on SDS PAGE. Protein quality was analyzed by Coomassie 
blue staining, while protein quantification was calculated by Western Blot 
using an anti-His antibody (sc57598, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). Protein bands were quantified from the standard curve 
fitting equation of GFP-H6 using the Quantity One software.
Cell Viability Assay: Cell viability of breast cancer cell lines (MDA-MB-
231, MDA-MB-468, BT-20, BT549, and HCC1187) upon treatment with 
IBs was measured by the MTT metabolic test (Roche, Basel, Switzerland) 
following manufacturer recommendations. MDA-MB-231, MDA-MB-
468, BT-20, BT549, and HCC1187 cells were plated at 2500 c/well, 
5000 c/well, 6000 c/well, 1000 c/well, and 6000 c/well respectively for 
24 h. Cells were incubated with 0.5, 1, and 3 × 10−6 m of IB protein. 
Viability was measured at 48, 72, and 96 h comparing luciferase signal 
against untreated control cells.
MDA-MB-231 Mammosphere Production: MDA-MB-231 cells were 
seeded at 1000 c/well in low attachment cell culture plates (Nunc, 
Waltham, MA, USA) and cultured in a defined media without serum[44] at 
37 °C and 5% CO2. After 5 and 7 d of incubation mammospheres appeared 
and cultures were challenged by the addition of 3 × 10−6 m FN-GFP-H6 
and FN-p31-H6 IB proteins and Omo-FN-H6 IB protein for 72 h. Sphere 
integrity and morphology were assessed by bright field imaging in an 
Olympus BH2 microscope (Olympus Corporation, Tokyo, Japan).
Field Emission Scanning Electron Microscopy: To characterize the 
morphometry (size and shape) at ultrastructural level of IBs at nearly 
native state, a rapid and easy method was used. Microdrops of 5 µL of 
diluted samples were deposited for 2 min on silicon wafers (Ted Pella Inc, 
Redding, CA, USA), liquid excess was blotted, air dried and immediately 
monitored without coating in a Field Emission Scanning Electron 
Microscope (FESEM) Zeiss Merlin (Carl Zeiss, Oberkochen, Germany) 
operating at 1 kV. IB images were collected with a standard secondary 
electron (SE) detector (4000–40,000x magnifications).
IB Labeling: AlexaFluor 647 NHS (Molecular Probes, Eugene, OR, 
USA) was used to label the inclusion bodies so that internalization 
assays could be normalized and compared at a unique wavelength. 
Conjugation was performed by resuspending IBs at 1 mg mL−1 in PBS 
with the addition of dye at a dye:protein molar ratio 2:1 and incubating 
for 1 h at RT with agitation. Serial cleaning steps were applied to 
remove free dye by centrifuging and resuspending the IBs with H2O. 
Fluorescence units/mass was determined by flow cytometry.
Confocal Laser Scanning Microscopy: MDA-MB-231 cells were seeded 
on Mat-Teck culture plate (Mat Teck Corporation, Ashland, MA, USA) at 
200 000 c/well for 24 h. Medium was removed and changed to OptiPRO 
serum-free medium supplemented with L-glutamine and 1 × 10−6 
m of IBs was added and incubated for 24 h. After incubation, cells 
were washed with PBS and 3 µg mL−1 WGA 594 (Molecular Probes) 
and 0.2 µg mL−1 Hoechst 33 342 (Molecular Probes) were added for 
5 min in darkness to visualize the plasma membrane and the nuclei 
respectively. Later, cells were washed with PBS and complete medium 
was added. Stained cells were examined using a TCS-SP5 confocal 
laser scanning microscope (Leica Microsystems, Heidelberg, Germany) 
with a Plan Apo 63 × /1.4 (oil HC × PL APO l blue) objective. Hoechst 
33 342, WGA 594 and Alexa Fluor 647 were excited by a blue diode 
(405 nm), a helium–neon laser (594 nm) and a helium–neon laser 
(633 nm) respectively. Z-series were collected at 0.5 mm intervals. 
Images were processed using Imaris version 6.1.0 software (Bitplane, 
Zürich, Switzerland).
Flow Cytometry: MDA-MB-231 cells were cultured on a 24 well plate 
at 80 000 c/well and incubated at 37 °C and 5% CO2 in a humidified 
atmosphere for 24 h. Cells were incubated with IBs at increasing 
concentrations and incubation times (internalization kinetics). After 
protein incubation, cells were treated with 1 mg mL−1 trypsin for 15 min 
to detach cells and remove unbound protein, followed by the addition of 
complete medium and centrifugation at 1400 g for 5 min. Collected cells 
were then resuspended in DPBS. Protein internalization was analyzed 
using a FACS-Canto system (Becton Dickinson, Franklin Lakes, NJ, 
USA), with a 15 W air-cooled red diode laser at 635 nm excitation. Alexa 
fluor 647 emission was measured with an FL4 detector (661/16 nm 
band pass filter). CD44-positive cells were determined as described.[45]
Human Cancer Animal Models: All the animal studies were performed 
in accordance with the ARRIVE guidelines and the 3 Rs (rules of 
Replacement, Reduction, and Refinement). Mice were housed and 
treated following the protocols approved by the Ethical Committee 
for the Use of Experimental Animals (CEEA) at the Vall d’Hebron 
Research Institute (VHIR), Barcelona. MDA-MB-231 cells, classified as 
mesenchymal-like,[46] were resuspended in cold PBS at 15 000 000 c mL−1 
and maintained on ice. Before surgery, mice were anesthetized with 
2% isoflurane and buprenorphine (0.75 mg kg−1) was administered 
subcutaneously. 100 µL (1 500 000 c/mouse were injected between the 
fourth and fifth right mammary fat pads of 8-week-old BALB/c nude 
female mice (n = 40). Tumor size was evaluated 2 times a week by 
caliper measurements and tumor volume calculated using the following 
formula: volume = (D × d2) / 2, where “D” is the largest diameter and 
“d” the smallest one. Weight of the mice was measured at least twice 
a week. When tumors reached a volume between 100 and 350 mm3, 
animals were randomized in the different groups (n = 7–8): control 
buffer (50 × 10−3 m KH2PO4, 500 × 10−3 m NaCl, 0.8 m Urea, 100 × 10−3 m  
GuHCl; pH 7.4), PBS, FNI/II/V-GFP-H6, and Omo-FNI/II/V-H6. Protein 
stocks were diluted to 4 g L−1 for the treatments. Animals were treated 
intratumorally once a week and the volume/dose of intratumoral 
administration was adjusted according to tumor volume (1:10 of the 
tumor volume was inoculated up to a maximum of 50 µL, e.g. a tumor 
of 220 mm3 was treated with 22 µL). Animals were treated up to 4 
weeks, then euthanized by CO2.
For biodistribution and efficacy studies, exponentially growing 
HCC1806 (2.5 × 106) or BT20 (10 × 106) cells, respectively, were 
orthotopically implanted into the fat mammary pad (i. f. m.p.) and 
monitored weekly as described above. These cells are classified as 
basal like[47] and luminal androgen receptor (LAR),[48] respectively. In 
biodistribution assays, once the tumors reached an average size of 
150 mm3, mice were intratumorally administered with Alexa 647 labeled 
FN-p31-H6 IBs (200 µg per mouse, n = 3) and fluorescent signal was 
monitored in vivo at different time periods post-administration by 
means of IVIS Spectrum equipment (Perkin Elmer, Tres Cantos, Spain). 
Quantification of the fluorescent signal (in Radiant Efficiency) was 
performed by using the Living Image software (Perkin Elmer). At the 
end point, tumors were excised and subjected to fluorescent imaging. 
Afterward, tissues were snap frozen and stored for further analysis or 
fixed in 4% formaldehyde and processed for histopathological analysis 
and evaluation. For efficacy assays, mice bearing BT20 tumors with an 
average size of 200 mm3 (n = 8), were administered with 600 µg of 
FN-p31-H6 or FN-GFP-H6 IBs. Administration was repeated twice in two 
week and animals were euthanized one week after the last treatment.
Tumor p21 Immunohistochemistry and Apoptosis: The presence of 
p21 antigen in tumor sections was analyzed by pre-treating paraffin 
embedded sections with 100 × 10−3 m citrate buffer (pH 9) in a cooker. 
Sections were incubated with 10% normal goat serum (NGS) in 
antibody diluent (1% BSA in 100 × 10−3 m Tris buffer) and then of 1:100 
dilution of anti-p21 antibody (M 7202, Dako, Santa Clara, CA, USA). 
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Secondary antibody consisted in a HRP conjugated system (EnVision+ 
System-HRP Labeled Polymer anti-Mouse), which was later visualized 
with DAB and counterstained with Harris haematoxylin. The p21 signal 
intensity and extension were scored under the light microscope by two 
blinded observers. Intensity cores ranged from 0 to 3 (absence, low 
intensity, normal or high, respectively). For each tumor, two independent 
sections with p21 staining were evaluated. For the evaluation of the 
extension of the apoptotic nuclei, sections were stained with Hoescht 
(1:500, Sigma-Aldrich, San Luis, MI, USA) mounted in Prolong 
(Invitrogen, Carlsbad, CA, USA). Two independent slides per tumor 
and five representative images per slide were analyzed after acquiring 
images at 10x magnification in an Olympus BX61 microscope (Olympus 
Corporation). In each image, the number of apoptotic nuclei versus the 
number of nonapoptotic nuclei was counted by two independent blinded 
observers. Results were presented as percentage of apoptotic nuclei. 
Anti-p21 (MS-891-B Thermo Scientific) Western Blot was performed 
on cell extracts as described[49] using BT20 cells exposed to 9 × 10−6 m 
protein for 4 h. Fold increase of p21 was referred to a β-actin control.
Statistical Analysis: Quantitative data were expressed as mean and 
standard error (x̄ ± SE). Depending on the type of data, parametric or 
nonparametric statistics were applied to compare divergences between 
all groups in relation to control or pairwise comparisons. In some data, 
one-way ANOVA followed by a post-hoc Dunnett was used, whereas 
Kruskall–Wallis and Mann Whitney or Wilcoxon tests were performed 
with the rest of data. Statistical significance levels were represented as 
n.s. p > 0.05, * p < 0.05, ** p < 0.01, and *** p < 0.001. All analyses were 
performed using SigmaPlot 10.0 software.
Acknowledgements
M.P. and T.J. contributed equally to this work. This study has been 
supported by La Fundació Marató TV3 and NanoCanTri (CIBER-BBN) 
to E.V. and I.A., and partially by ISCIII (PI15/00272 and PI1702242 
co-founded by Fondo Europeo de Desarrollo Regional (FEDER), to 
E.V. and S.S., respectively), and Agencia Estatal de Investigación (AEI) 
and FEDER (BIO2016-76063-R, AEI/FEDER, UE), AGAUR (2017SGR-229) 
and CIBER-BBN (VENOM4CANCER) granted to A.V. Protein production 
and DLS have been partially performed by the ICTS “NANBIOSIS,” 
more specifically by the Protein Production Platform of CIBER-BBN/IBB 
(http://www.nanbiosis.es/unit/u1-protein-production-platform-ppp/) 
and the Biomaterial Processing and Nanostructuring Unit (http://www.
nanbiosis.es/portfolio/u6-biomaterial-processing-and-nanostructuring-
unit/), respectively. Biodistribution and immunohistochemistry assays 
were performed at the ICTS “NANBIOSIS,” specifically by U20/FVPR 
(http://www.nanbiosis.es/portfolio/u20-in-vivo-experimental-platform/). 
L.S.-G. was supported by predoctoral fellowship from AGAUR (2018FI_
B2_00051). L.S. was supported by the European Research Council (CoG 
#617473) and the Instituto de Salud Carlos III (FIS #PI16/01224). J.S.-F. 
was supported by an AECC post-doctoral fellowship. A.V. received an 
ICREA ACADEMIA award.
Conflict of Interest
T.J. is an employee of Peptomyc S.L.; L.S. and M.E.B. are co-founders 
and shareholders of the same company.
Keywords
biofabrication, cancer therapy, functional amyloids, inclusion bodies, 
protein drug release
Received: April 12, 2019
Revised: June 11, 2019
Published online: 
[1] A. de Marco, N. Ferrer-Miralles, E. Garcia-Fruitos, A. Mitraki, 
S. Peternel, U. Rinas, M. A. Trujillo-Roldan, N. A. Valdez-Cruz, 
E. Vazquez, A. Villaverde, FEMS Microbiol. Rev. 2019, 43, 53.
[2] a) L. Wang, S. K. Maji, M. R. Sawaya, D. Eisenberg, R. Riek, PLoS 
Biol. 2008, 6, e195; b) L. Wang, Prion 2009, 3, 139.
[3] O. Cano-Garrido, E. Rodriguez-Carmona, C. Diez-Gil, E. Vazquez, 
E. Elizondo, R. Cubarsi, J. Seras-Franzoso, J. L. Corchero, U. Rinas, 
I. Ratera, N. Ventosa, J. Veciana, A. Villaverde, E. Garcia-Fruitos, 
Acta Biomater. 2013, 9, 6134.
[4] E. Garcia-Fruitos, E. Rodriguez-Carmona, C. Diez-Gil, R. M. Ferraz, 
E. Vazquez, J. L. Corchero, M. Cano-Sarabia, I. Ratera, N. Ventosa, 
J. Veciana, A. Villaverde, Adv. Mater. 2009, 21, 4249.
[5] A. Villaverde, E. Garcia-Fruitos, U. Rinas, J. Seras-Franzoso, 
A. Kosoy, J. L. Corchero, E. Vazquez, Microb. Cell Fact. 2012, 11, 76.
[6] N. Gonzalez-Montalban, E. Garcia-Fruitos, A. Villaverde, Nat. Bio-
technol. 2007, 25, 718.
[7] a) E. Hrabarova, L. Achbergerova, J. Nahalka, Methods Mol. Biol. 
2015, 1258, 411; b) V. D. Jager, R. Kloss, A. Grunberger, S. Seide, 
D. Hahn, T. Karmainski, M. Piqueray, J. Embruch, S. Longerich, 
U. Mackfeld, K. E. Jaeger, W. Wiechert, M. Pohl, U. Krauss, Microb. 
Cell Fact. 2019, 18, 33.
[8] E. Vazquez, J. L. Corchero, J. F. Burgueno, J. Seras-Franzoso, 
A. Kosoy, R. Bosser, R. Mendoza, J. M. Martinez-Lainez, U. Rinas, 
E. Fernandez, L. Ruiz-Avila, E. Garcia-Fruitos, A. Villaverde, Adv. 
Mater. 2012, 24, 1742.
[9] J. Seras-Franzoso, A. Sanchez-Chardi, E. Garcia-Fruitos, E. Vazquez, 
A. Villaverde, Soft Matter 2016, 12, 3451.
[10] a) M. Liovic, M. Ozir, A. B. Zavec, S. Peternel, R. Komel, 
T. Zupancic, Microb. Cell Fact. 2012, 11, 67. b) K. Talafova, 
E. Hrabarova, D. Chorvat, J. Nahalka, Microb. Cell Fact. 2013, 12, 16.
[11] A. Stamm, S. Strauss, P. Vogt, T. Scheper, I. Pepelanova, Microb. 
Cell Fact. 2018, 17, 57.
[12] U. Unzueta, M. V. Cespedes, R. Sala, P. Alamo, A. Sanchez-Chardi, 
M. Pesarrodona, L. Sanchez-Garcia, O. Cano-Garrido, A. Villaverde, 
E. Vazquez, R. Mangues, J. Seras-Franzoso, J. Controlled Release 
2018, 279, 29.
[13] M. V. Cespedes, Y. Fernandez, U. Unzueta, R. Mendoza, 
J. Seras-Franzoso, A. Sanchez-Chardi, P. Alamo, V. Toledo-Rubio, 
N. Ferrer-Miralles, E. Vazquez, S. Schwartz, I. Abasolo, 
J. L. Corchero, R. Mangues, A. Villaverde, Sci. Rep. 2016, 6, 35765.
[14] S. K. Maji, M. H. Perrin, M. R. Sawaya, S. Jessberger, K. Vadodaria, 
R. A. Rissman, P. S. Singru, K. P. Nilsson, R. Simon, D. Schubert, 
D. Eisenberg, J. Rivier, P. Sawchenko, W. Vale, R. Riek, Science 2009, 
325, 328.
[15] a) M. P. Badtke, N. D. Hammer, M. R. Chapman, Sci. Sign-
aling 2009, 2, pe43; b) K. Schwartz, A. K. Syed, R. E. Stephenson, 
A. H. Rickard, B. R. Boles, PLoS Pathog. 2012, 8, e1002744;  
c) P. Falabella, L. Riviello, M. Pascale, I. D. Lelio, G. Tettamanti, 
A. Grimaldi, C. Iannone, M. Monti, P. Pucci, A. M. Tamburro, 
M. Deeguileor, S. Gigliotti, F. Pennacchio, Insect Biochem. Mol. 
Biol. 2012, 42, 203; d) A. K. Syed, B. R. Boles, Front. Microbiol. 
2014, 5, 401; e) D. Romero, R. Kolter, Int. Microbiol. 2014, 17, 65; 
f) B. Guyonnet, N. Egge, G. A. Cornwall, Mol. Cell. Biol. 2014, 34, 
2624; g) T. Seviour, S. H. Hansen, L. Yang, Y. H. Yau, V. B. Wang, 
M. R. Stenvang, G. Christiansen, E. Marsili, M. Givskov, Y. Chen, 
D. E. Otzen, P. H. Nielsen, S. Geifman-Shochat, S. Kjelleberg, 
M. S. Dueholm, J. Biol. Chem. 2015, 290, 6457; h) S. M. Lyons, 
P. Anderson, Dev. Cell 2016, 39, 131; i) M. L. Daus, Biology 2016, 5, 2. 
j) K. Schwartz, M. Ganesan, D. E. Payne, M. J. Solomon, B. R. Boles, 
Mol. Microbiol. 2016, 99, 123; k) L. Molina-Garcia, F. Gasset-Rosa, 
M. Moreno-Del Alamo, M. E. Fernandez-Tresguerres, 
S. Moreno-Diaz de la Espina, R. Lurz, R. Giraldo, Sci. Rep. 2016, 
6, 25425; l) M. P. Jackson, E. W. Hewitt, Biomolecules 2017, 7, 71. 
m) A. Dragos, A. T. Kovacs, D. Claessen, Biomolecules 2017, 7, 
60. n) A. Piscitelli, P. Cicatiello, A. M. Gravagnuolo, I. Sorrentino, 
www.advancedsciencenews.com
1900849 (9 of 9) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
Adv. Sci. 2019, 1900849
C. Pezzella, P. Giardina, Biomolecules 2017, 7, 45. o) A. Hewetson, 
H. Q. Do, C. Myers, A. Muthusubramanian, R. B. Sutton, 
B. J. Wylie, G. A. Cornwall, Biomolecules 2017, 7, 46. p) R. N. Besingi, 
I. B. Wenderska, D. B. Senadheera, D. G. Cvitkovitch, J. R. Long, 
Z. T. Wen, L. J. Brady, Microbiology 2017, 163, 488; q) N. Van Gerven, 
S. E. Van der Verren, D. M. Reiter, H. Remaut, J. Mol. Biol. 2018. 
430, 3657.
[16] I. Casanova, M. Parreno, L. Farre, S. Guerrero, M. V. Cespedes, 
M. A. Pavon, F. J. Sancho, E. Marcuello, M. Trias, R. Mangues, Int. 
J. Cancer 2006, 118, 2381.
[17] W. Kim, S. Kook, D. J. Kim, C. Teodorof, W. K. Song, J. Biol. Chem. 
2004, 279, 8333.
[18] L. Soucek, M. Helmer-Citterich, A. Sacco, R. Jucker, G. Cesareni, 
S. Nasi, Oncogene 1998, 17, 2463.
[19] J. R. Whitfield, M. E. Beaulieu, L. Soucek, Front. Cell Dev. Biol. 2017, 
5, 10.
[20] L. Soucek, J. Whitfield, C. P. Martins, A. J. Finch, D. J. Murphy, 
N. M. Sodir, A. N. Karnezis, L. B. Swigart, S. Nasi, G. I. Evan, 
Nature 2008, 455, 679.
[21] a) L. Soucek, J. R. Whitfield, N. M. Sodir, D. Masso-Valles, 
E. Serrano, A. N. Karnezis, L. B. Swigart, G. I. Evan, Genes Dev. 
2013, 27, 504; b) N. M. Sodir, L. B. Swigart, A. N. Karnezis, 
D. Hanahan, G. I. Evan, L. Soucek, Genes Dev. 2011, 25, 
907.
[22] a) V. Orian-Rousseau, Eur. J. Cancer 2010, 46, 1271; 
b) A. Matzke-Ogi, K. Jannasch, M. Shatirishvili, B. Fuchs, 
S. Chiblak, J. Morton, B. Tawk, T. Lindner, O. Sansom, F. Alves, 
A. Warth, C. Schwager, W. Mier, J. Kleeff, H. Ponta, A. Abdollahi, 
V. Orian-Rousseau, Gastroenterology 2016, 150, 513.
[23] a) M. Culty, M. Shizari, E. W. Thompson, C. B. Underhill, J. Cell. 
Physiol. 1994, 160, 275; b) G. Tzircotis, R. F. Thorne, C. M. Isacke, 
J. Cell Sci. 2005, 118, 5119.
[24] C. Sheridan, H. Kishimoto, R. K. Fuchs, S. Mehrotra, 
P. Bhat-Nakshatri, C. H. Turner, R. Goulet Jr., S. Badve, 
H. Nakshatri, Breast Cancer Res. 2006, 8, R59.
[25] C. A. Hudis, L. Gianni, Oncologist 2011, 16, 1.
[26] M. Pesarrodona, N. Ferrer-Miralles, U. Unzueta, P. Gener, 
W. Tatkiewicz, I. Abasolo, I. Ratera, J. Veciana, S. Schwartz Jr., 
A. Villaverde, E. Vazquez, Int. J. Pharm. 2014, 473, 286.
[27] S. Peternel, R. Komel, Int. J. Mol. Sci. 2011, 12, 8275.
[28] E. Garcia-Fruitos, J. Seras-Franzoso, E. Vazquez, A. Villaverde, 
Nanotechnology 2010, 21, 205101.
[29] G. Chang, J. Wang, H. Zhang, Y. Zhang, C. Wang, H. Xu, H. Zhang, 
Y. Lin, L. Ma, Q. Li, T. Pang, Br. J. Cancer 2014, 110, 916.
[30] U. Unzueta, J. Seras-Franzoso, M. V. Cespedes, P. Saccardo, 
F. Cortes, F. Rueda, E. Garcia-Fruitos, N. Ferrer-Miralles, 
R. Mangues, E. Vazquez, A. Villaverde, Nanotechnology 2017, 28, 
015102.
[31] a) H. Lincet, L. Poulain, J. S. Remy, E. Deslandes, F. Duigou, 
P. Gauduchon, C. Staedel, Cancer Lett. 2000, 161, 17; b) Q. Wu, 
P. Kirschmeier, T. Hockenberry, T. Y. Yang, D. L. Brassard, L. Wang, 
T. McClanahan, S. Black, G. Rizzi, M. L. Musco, A. Mirza, S. Liu, 
J. Biol. Chem. 2002, 277, 36329; c) K. Yang, X. Y. Zheng, J. Qin, 
Y. B. Wang, Y. Bai, Q. Q. Mao, Q. Wan, Z. M. Wu, L. P. Xie, 
Cancer Lett. 2008, 265, 206; d) M. S. Sheikh, H. Rochefort, 
M. Garcia, Oncogene 1995, 11, 1899; e) S. Kondo, B. P. Barna, 
Y. Kondo, Y. Tanaka, G. Casey, J. Liu, T. Morimura, R. Kaakaji, 
J. W. Peterson, B. Werbel, G. H. Barnett, Oncogene 1996, 
13, 1279.
[32] a) Y. Loo, M. Goktas, A. B. Tekinay, M. O. Guler, C. A. Hauser, 
A. Mitraki, Adv. Healthcare Mater. 2015, 4, 2557; b) T. D. Sutherland, 
M. G. Huson, T. D. Rapson, J. Struct. Biol. 2018, 201, 76;  
c) T. O. Yeates, Annu. Rev. Biophys. 2017, 46, 23; d) I. W. Hamley, 
Biomacromolecules 2019, 20, 1829.
[33] S. Mahanta, S. Paul, ACS Appl. Mater. Interfaces 2015, 7, 28177.
[34] S. Mahanta, S. Paul, A. Srivastava, A. Pastor, B. Kundu, 
T. K. Chaudhuri, Colloids Surf., B 2015, 130, 237.
[35] U. Rinas, E. Garcia-Fruitós, J. L. Corchero, E. Vázquez, 
J. Seras-Franzoso, Trends Biochem. Sci. 2017, 42, 726.
[36] D. Torrealba, J. Seras-Franzoso, U. Mamat, K. Wilke, A. Villaverde, 
N. Roher, E. Garcia-Fruitos, PLoS One 2016, 11, e0164073.
[37] a) J. Seras-Franzoso, K. Peebo, E. Garcia-Fruitos, E. Vazquez, 
U. Rinas, A. Villaverde, Acta Biomater. 2014, 10, 1354;  
b) J. Seras-Franzoso, W. I. Tatkiewicz, E. Vazquez, E. Garcia-Fruitos, 
I. Ratera, J. Veciana, A. Villaverde, Nanomedicine 2015, 10, 873.
[38] E. Garcia-Fruitos, E. Vazquez, C. Diez-Gil, J. L. Corchero, 
J. Seras-Franzoso, I. Ratera, J. Veciana, A. Villaverde, Trends 
Biotechnol. 2012, 30, 65.
[39] A. R. Wasylishen, L. Z. Penn, Genes Cancer 2010, 1, 532.
[40] M. E. Beaulieu, T. Jauset, D. Masso-Valles, S. Martinez-Martin, 
P. Rahl, L. Maltais, M. F. Zacarias-Fluck, S. Casacuberta-Serra, 
E. Serrano Del Pozo, C. Fiore, L. Foradada, V. C. Cano, 
M. Sanchez-Hervas, M. Guenther, E. Romero Sanz, M. Oteo, 
C. Tremblay, G. Martin, D. Letourneau, M. Montagne, 
M. A. Morcillo Alonso, J. R. Whitfield, P. Lavigne, L. Soucek, Sci. 
Transl. Med. 2019, 11. eaar5012.
[41] E. Wang, A. Sorolla, P. T. Cunningham, H. M. Bogdawa, S. Beck, 
E. Golden, R. E. Dewhurst, L. Florez, M. N. Cruickshank, 
K. Hoffmann, R. M. Hopkins, J. Kim, A. J. Woo, P. M. Watt, 
P. Blancafort, Oncogene 2019, 38, 140.
[42] R. Z. Liu, T. M. Vo, S. Jain, W. S. Choi, E. Garcia, E. A. Monckton, 
J. R. Mackey, R. Godbout, J. Pathol. 2019, 247, 186.
[43] a) D. Agyei, I. Ahmed, Z. Akram, H. M. Iqbal, M. K. Danquah, 
Protein Pept. Lett. 2017, 24, 94; b) J. M. Reichert, C. Paquette, 
Curr. Opin. Mol. Ther. 2003, 5, 139; c) J. A. DiMasi, J. M. Reichert, 
L. Feldman, A. Malins, Clin. Pharmacol. Ther. 2013, 94, 329;  
d) T. Butler, S. Maravent, J. Boisselle, J. Valdes, C. Fellner, P T 2015, 
40, 191.
[44] P. Gener, L. P. Gouveia, G. R. Sabat, D. F. de Sousa Rafael, 
N. B. Fort, A. Arranja, Y. Fernandez, R. M. Prieto, J. S. Ortega, 
D. Arango, I. Abasolo, M. Videira, S. Schwartz Jr., Nanomedicine 
2015, 11, 1883.
[45] M. Naruse, K. Shibasaki, S. Yokoyama, M. Kurachi, Y. Ishizaki, PLoS 
One 2013, 8, e53109.
[46] J. L. Yori, E. Johnson, G. Zhou, M. K. Jain, R. A. Keri, J. Biol. Chem. 
2010, 285, 16854.
[47] M. van Geldermalsen, Q. Wang, R. Nagarajah, A. D. Marshall, 
A. Thoeng, D. Gao, W. Ritchie, Y. Feng, C. G. Bailey, N. Deng, 
K. Harvey, J. M. Beith, C. I. Selinger, S. A. O’Toole, J. E. Rasko, 
J. Holst, Oncogene 2016, 35, 3201.
[48] G. Sflomos, V. Dormoy, T. Metsalu, R. Jeitziner, L. Battista, 
V. Scabia, W. Raffoul, J. F. Delaloye, A. Treboux, M. Fiche, J. Vilo, 
A. Ayyanan, C. Brisken, Cancer Cell 2016, 29, 407.
[49] L. Lupini, F. Pepe, M. Ferracin, C. Braconi, E. Callegari, S. Pagotto, 
R. Spizzo, B. Zagatti, P. Lanuti, F. Fornari, R. Ghasemi, 
R. Mariani-Costantini, L. Bolondi, L. Gramantieri, G. A. Calin, 
S. Sabbioni, R. Visone, A. Veronese, M. Negrini, Oncotarget 2016, 
7, 31361.
